Search

Your search keyword '"Van Der Wall, Elsken"' showing total 945 results

Search Constraints

Start Over You searched for: Author "Van Der Wall, Elsken" Remove constraint Author: "Van Der Wall, Elsken" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
Sorry, I don't understand your search. ×
945 results on '"Van Der Wall, Elsken"'

Search Results

2. Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

4. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer

8. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study

10. Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.

17. Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study

18. Off to a good start after a cancer diagnosis: implementation of a time out consultation in primary care before cancer treatment decision

21. Effect of Physical Exercise on MRI‐Assessed Brain Perfusion in Chemotherapy‐Treated Breast Cancer Patients: A Randomized Controlled Trial.

23. Effects of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity

26. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018

27. Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer

28. Effects of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity

29. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer

30. Time Trends in Histopathological Findings in Mammaplasty Specimens in a Dutch Academic Pathology Laboratory

31. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study

34. Data from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer

35. Supplementary Figure 1 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

36. Supplementary Figure 7 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

37. Supplementary Figure 6 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

38. Supplemental Movie S1. Explanatory Movie of Multiplex Advanced Pathology Imaging (MAPI). from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

39. Supplementary Figure 4 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

40. Supplementary Figure 5 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

41. Supplemental Materials and Methods and Supplementary Figures 1 and 2 from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer

42. Supplementary Figure 3 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

43. Supplementary Figure 2 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

44. Supplemental Material and Methods from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

45. Supplementary Figure 2 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling

46. Supplementary Figure 3 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling

47. Supplementary Figure Legends from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling

48. Supplementary Figure 5 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling

49. Supplementary Figure 6 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling

50. Supplementary Figure 1 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling

Catalog

Books, media, physical & digital resources